Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Berger on Benefits of New Screening Test for CRC

October 11th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses Cologuard screening test for colorectal cancer (CRC).

Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

October 9th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

Dr. Bruix on the Phase III RESORCE Trial in HCC

October 8th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib

October 8th 2016

The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.

Dr. Heinemann on Implications of SIRFLOX Study for mCRC

October 7th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the broad clinical implications of the SIRFLOX findings for patients with metastatic colorectal cancer (mCRC).

Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer

September 29th 2016

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.

Dr. Matthew Yurgelun on Pathogenic Mutations in CRC

September 22nd 2016

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

September 21st 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

September 20th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses regorafenib and TAS-102. In colorectal cancer.

Dr. Finn on Recent Advances in the Treatment of Liver Cancer

September 20th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Dr. Bekaii-Saab on Microsatellite Instability in Colorectal Cancer

September 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability in colorectal cancer.

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

September 14th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

September 14th 2016

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Conflicting Evidence Surfaces on Anti-HCV Drugs for Liver Cancer

September 12th 2016

A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

September 12th 2016

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

New Roles May Evolve for Competing Embolization Techniques in HCC

September 12th 2016

Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.

Dr. Do on the Assessment of Tumor Response in Liver Cancer

September 11th 2016

Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in liver cancer.

Dr. Yao on the Milan Criteria in Liver Cancer

September 11th 2016

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC

September 11th 2016

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Nivolumab Maintains Positive Results in Latest HCC Findings

September 11th 2016

Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.